References
- Tans G, Bouma BN, Büller HR, Rosing J. Changes of hemostatic variables
during oral contraceptive use. Semin Vasc Med 2003; 3 (1): 61-68.
- O’Brien SH. Contraception-Related Venous Thromboembolism in
Adolescents. Semin Thromb Hemost 2014; 40: 66-71.
- Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis
in users of non-oral hormonal contraception: follow up study, Denmark
2001-10. BMJ 2012; 344: e2990.
- Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E.
Risk of venous thromboembolism from use of oral contraceptives
containing different progestogens and estrogen doses: Danish cohort
study 2001-9 BMJ 2011; 343: d6423.
- Jick SS, Kaye JA, Russman S, Jick H. Risk of nonfatal venous
thromboembolism with oral contraceptives containing norgestimate or
desogestrel compared with oral contraceptives containing
levonorgestrel. Contraception 2006; 73 (6): 566-70.
- Ogden CL, Carroll ED, Fryar CD et al. Prevalence of obesity among
adults and youth United States 2011-2014: NCHS Data Brief 2015; (219):
1-8.
- Ward Z, Bleich SN, Cradock AL, Barrett JL et al. Projected U.S
State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J
Med 2019; 381: 2440-2450.
- Pannaciulli N, DeMitrio V, Marino R et al. Effect of glucose tolerance
status on PAI-1 plasma levels in overweight and obese subjects. Obes
Res 2002; 10: 17-25.
- Juhar-Vague I, Alessi MC, Mauri A et al. Plasminogen activator
inhibitor-1, inflammation, obesity, insulin resistance and vascular
risk. J Thromb Haemost 2003; 1: 1575-1579.
- Mertens I, Van Gall LF. Obesity, haemostasis and the fibrinolytic
system. Obes Rev 2002; 3: 85-101.
- Sydney S, Petitti DB, Soff GA et al. Venous thromboembolic disease in
users of low-estrogen combined estrogen-progestin oral contraceptives.
Contraception. 2004; 70: 3-10.
- Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use
among obese women and risk for cardiovascular events; A systematic
review. Contraception 2016; 94: 590-604.
- Abdollahi M, Cushman M, Roseendal FR. Obesity: risk of venous
thrombosis and the interaction with coagulation factor levels and oral
contraceptive use. Thromb Haemost 2003; 89: 493.
- Pomp ER, LeCessie S, Rosendaal FR et al. Risk of venous thrombosis:
obesity and its joint effect with oral contraceptive use as
prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
- Lidegaard O, Kreiner S. Contraceptives and cerebral thrombosis: a five
year national case-control study. Contraception 2002; 65 (3): 197-205.
- Pillai P, Bonny AE, O’Brien SH. Contraception-related venous
thromboembolism in a Pediatric Institution. J Pediatr Adolesc Gynecol
2013; 26: 186-188.
- Conard J. Biological coagulation findings in third-generation oral
contraceptives. Hum Reprod Update . 1999;5(6):672-680.
- Jeanet M. Kemmeren, Ale Algra, Joost C. M. Meijers, Guido Tans, Bonno
N. Bouma, Joyce Curvers, Jan Rosing, Diederick E. Grobbee; Effect of
second- and third-generation oral contraceptives on the protein C
system in the absence or presence of the factor
VLeiden mutation: a randomized
trial. Blood 2004; 103 (3): 927–933.
- Merki-Feld GS, Skouby S, Serfaty D et al. European Society of
contraception Statement on contraception in obese women. Eu J
Contracept Reprod Health Care 2015; 20: 19-28.
- Van Vlijmen EF, Veeger NJ, Middeldorp S et al. Thrombotic risk during
oral contraceptive use and pregnancy in women with Factor V Leiden or
prothrombin mutation: a rational approach to contraception. Blood
2011; 118 (8): 2055-2061.
- Lidegaard O. Hormonal contraception, thrombosis and age. Expert Opin
Drug Saf 2014; 13 (10): 1353-1360.
- Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis
associated with drospirenone-containing oral contraceptives: a
population-based cohort study. CMAJ . 2011;183(18):E1319-E1325.
- Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A
systematic review and meta-analysis of venous thrombosis risk among
users of combined oral contraception. Int J Gynaecol Obstet.
2018;141(3):287-294.
- World Health Organization Medical Eligibility Criteria for
Contraceptive Use. Geneva, Switzerland: World Health Organization:
2009.
- Faculty of Sexual & Reproductive Health-Care. UK medical eligibility
for contraceptive use. Available at www.
Ffprhc.org.uk/admin/uploads/UKMEC 2009.pdf. Accessed December 23,
2019.
- Division of Reproductive Health, National Center for Chronic Disease
Prevention and Health Promotion: Centers for Disease Control and
Prevention; Farr S, Folger SG, Paulen M, et al. US medical eligibility
criteria for contraceptive use, 2010: adapted from the World Health
Organization Medical Eligibility Criteria for Contraceptive Use,
4th ed. MMWR Recomm Rep 2010; 59 (RR-4). 1-86.